Document is current
Any future updates will be listed below
-
Authors
Takami, Akina https://orcid.org/0009-0004-3289-822X
Terashima, Gen https://orcid.org/0000-0002-6804-5585
Tajima, Takumi https://orcid.org/0009-0007-9633-5831
Yamashita, Koki https://orcid.org/0009-0005-3187-0900
Igarashi, Ataru https://orcid.org/0000-0001-6307-6916
-
Funding
Funding for this research was provided by:
University of Tokyo
- License Information
-
More Information
Article History
Accepted: 9 January 2025
First Online: 31 January 2025
Declarations
:
: No funding was received for the conduct of this study or the preparation of this article.
: Ethics approval was not applicable to this study based on the Ethical Guidelines for Medical and Health Research Involving Human Subjects issued by the MHLW, since only completely encrypted data were used.
: Not applicable.
: Not applicable.
: Not applicable.
: The datasets generated for this manuscript are available in the JADER database ().
: Not applicable.
: Akina Takami developed the concept and the study design; Akina Takami, Gen Terashima, and Takumi Tajima analyzed the data; and all authors wrote, reviewed, and approved the final version of the manuscript.
: Akina Takami and Ataru Igarashi are members of the Department of Health Policy and Public Health (formerly known as the Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, which received an unrestricted grant from Takeda Pharmaceutical Co. Ltd.); Gen Terashima and Takumi Tajima are employees of JMDC, Inc.; Koki Yamashita is the president of Maxwell International, Inc., wherein he provides medical writing and clinical study consultation services to academic, pharmaceutical, biotechnology, and medical device entities; and Ataru Igarashi reports receiving remuneration from AstraZeneca K.K.
